Prognostic value of heart rate variability footprint and standard deviation of average 5-minute intrinsic R-R intervals for mortality in cardiac resynchronization therapy patients

被引:19
作者
Gilliam, F. Roosevelt, III [1 ]
Singh, Jagmeet P.
Mullin, Christopher M.
McGuire, Maureen
Chase, Kellie J.
机构
[1] NE Arkansas, Jonesboro, AR 72401 USA
[2] Massachusetts Gen Hosp, Boston, MA 02114 USA
[3] Integra Grp, Brooklyn Pk, MN USA
[4] Boston Sci CRM, St Paul, MN USA
关键词
heart failure; heart rate; mortality; cardiac resynchronization therapy; FAILURE; TRIAL; CARDIOMYOPATHY; DEVICE;
D O I
10.1016/j.jelectrocard.2006.11.012
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Cardiac resynchronization therapy devices provide effective therapy for heart failure. Heart rate variability (HRV) parameters in the device such as HRV footprint and SD of average 5-minute intrinsic R-R intervals (SDANN) are related to autonomic function and may be used to identify patients with a higher risk of mortality. Methods: We examined the relationship between HRV and mortality in a prospective cohort study. The 842 patients (mean age, 67.7 +/- 11.2; 23.5 % female; New York Heart Association class III, 88.6%; class IV, 11.4%) included in the analysis were implanted with a cardiac resynchronization therapy with defibrillation device and had baseline HRV measurements available. Results: During a median of 11.6 months of follow-up, 7.8% (66/842) of patients died. Heart rate variability footprint and SDANN were significant predictors of mortality (all P <.05); patients with lower HRV values were at greater risk for death, compared with patients with higher HRV values. Heart rate variability changes over time tended to predict the risk of mortality in follow-up (P nonsignificant), ; patients with low baseline HRV and small changes in HRV during the follow-up period were at the highest risk for death (7% mortality for SDANN and 8.9% for HRV footprint), and patients with high baseline HRV and large changes in HRV were at the lowest risk (1.5% mortality for SDANN and 2.4% for HRV footprint). Results were consistent when adjusted for age, sex, body mass index, and diastolic blood pressure. Conclusions: Continuously measured device HRV parameters provide prognostic information about patient mortality that may be helpful for risk stratification. (c) 2007 Elsevier Inc. All rights reserved.
引用
收藏
页码:336 / 342
页数:7
相关论文
共 20 条
  • [1] Cardiac resynchronization in chronic heart failure
    Abraham, WT
    Fisher, WG
    Smith, AL
    Delurgio, DB
    Leon, AR
    Loh, E
    Kocovic, DZ
    Packer, M
    Clavell, AL
    Hayes, DL
    Ellestad, M
    Messenger, J
    Trupp, RJ
    Underwood, J
    Pickering, F
    Truex, C
    McAtee, P
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2002, 346 (24) : 1845 - 1853
  • [2] Continuous autonomic assessment in patients with symptomatic heart failure - Prognostic value of heart rate variability measured by an implanted cardiac resynchronization device
    Adamson, PB
    Smith, AL
    Abraham, WT
    Kleckner, KJ
    Stadler, RW
    Shih, A
    Rhodes, MM
    [J]. CIRCULATION, 2004, 110 (16) : 2389 - 2394
  • [3] Cardiac resynchronization therapy improves heart rate variability in patients with symptomatic heart failure
    Adamson, PB
    Kleckner, KJ
    VanHout, WL
    Srinivasan, S
    Abraham, WT
    [J]. CIRCULATION, 2003, 108 (03) : 266 - 269
  • [4] *AM HEART ASS, 2005 HEART STROK STA
  • [5] Prognostic value of heart rate variability in chronic congestive heart failure (veterans affairs' survival trial of antiarrhythmic therapy in congestive heart failure)
    Bilchick, KC
    Fetics, B
    Djoukeng, R
    Fisher, SG
    Fletcher, RD
    Singh, SN
    Nevo, E
    Berger, RD
    [J]. AMERICAN JOURNAL OF CARDIOLOGY, 2002, 90 (01) : 24 - 28
  • [6] PROGNOSTIC VALUE OF HEART-RATE-VARIABILITY IN PATIENTS AWAITING CARDIAC TRANSPLANTATION
    BINDER, T
    FREY, B
    PORENTA, G
    HEINZ, G
    WUTTE, M
    KREINER, G
    GOSSINGER, H
    SCHMIDINGER, H
    PACHER, R
    WEBER, H
    [J]. PACE-PACING AND CLINICAL ELECTROPHYSIOLOGY, 1992, 15 (11): : 2215 - 2220
  • [7] Monitoring of physical activity and heart rate variability in patients with chronic heart failure using cardiac resynchronization devices
    Braunschweig, F
    Mortensen, PT
    Gras, D
    Reiser, W
    Lawo, T
    Mansour, H
    Sogaard, P
    Stegemann, B
    Bruns, HJ
    Linde, C
    [J]. AMERICAN JOURNAL OF CARDIOLOGY, 2005, 95 (09) : 1104 - 1107
  • [8] Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure
    Bristow, MR
    Saxon, LA
    Boehmer, J
    Krueger, S
    Kass, DA
    De Marco, T
    Carson, P
    DiCarlo, L
    DeMets, D
    White, BG
    DeVries, DW
    Feldman, AM
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (21) : 2140 - 2150
  • [9] Three-dimensional heart rate variability diagnostic for monitoring heart failure through an implantable device
    Carlson, G
    Girouard, S
    Schlegl, M
    Butter, C
    [J]. JOURNAL OF CARDIOVASCULAR ELECTROPHYSIOLOGY, 2004, 15 (04) : 506 - 506
  • [10] The effect of cardiac resynchronization on morbidity and mortality in heart failure
    Cleland, JGF
    Daubert, J
    Erdmann, E
    Freemantle, N
    Gras, D
    Kappenberger, L
    Tavazzi, L
    Cleland, JGF
    Daubert, JC
    Erdmann, E
    Gras, D
    Kappenberger, L
    Klein, W
    Tavazzi, L
    Poole-Wilson, PA
    Rydén, L
    Wedel, H
    Wellens, HJJ
    Uretsky, B
    Thygesen, K
    Böcker, D
    Marijianowski, MMH
    Freemantle, N
    Calvert, MJ
    Christ, G
    Fruhwald, F
    Hofmann, R
    Krypta, A
    Leisch, F
    Pacher, R
    Rauscha, F
    Tavernier, R
    Thomsen, PEB
    Boesgaard, S
    Eiskjær, H
    Esperen, GT
    Haarbo, J
    Hagemann, A
    Korup, E
    Moller, M
    Mortensen, P
    Sogaard, P
    Vesterlund, T
    Huikuri, H
    Niemelä, KI
    Toivonen, L
    Bauer, F
    Cohen-Solal, A
    Crocq, C
    Djiane, P
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2005, 352 (15) : 1539 - 1549